Madrigal, BeiGene, and Biotech Alpha: Inside the “Gene-ius” Kingmakers of Baker Bros. 2025

🎯 FunFund Index™: 9.5 / 10 🎯

🧪 Tooltip explainer: A near-perfect score means rare skill, repeatable edge, and disciplined execution across cycles—not just a lucky year.

In the world of biotech, there are “investors”… and then there are the Baker Brothers.

While the average biotech ETF spent the early 2020s in something that felt suspiciously like a medically induced coma 😴, Julian and Felix Baker were quietly building what can only be described as a Fortress of Science. By mid-2025, that patience paid off in spectacular fashion: one widely cited estimate puts their trailing 12-month return at ~67.8% as of September 2025. That’s not a typo. That’s a mic drop. 🎤

Managing roughly $13.8B to $18B depending on the quarter, Baker Bros. Advisors didn’t just participate in the biotech recovery—they engineered it. Their approach is unapologetically high-conviction: the top 10 holdings represent close to 80% of the entire portfolio. Diversification is for people who don’t know what they own. The Bakers? They want ownership with a PhD.

🧠 The 2025 Playbook: “The Long Game” in Action

One of their largest pillars remains BeiGene (BGNE)—a roughly $3B position and a global oncology powerhouse that would give most compliance departments mild palpitations due to its China roots. The Bakers don’t flinch. They read molecules, not headlines. 🧬

But the real Madrigal of 2025 (yes, we’re keeping the pun 🎻) was Madrigal Pharmaceuticals (MDGL).

As Rezdiffra, the first FDA-approved drug for MASH (fatty liver disease), moved from “promising science” to commercial reality, the Bakers didn’t trim. They added. In August alone, they piled in with roughly $60M+ of additional conviction. By year-end, Rezdiffra was treating 29,500+ patients, with sales annualizing toward $1B+. That’s not hope—that’s execution.

At the same time, they showed discipline:

• ✂️ Trimmed Insmed and argenx

• 🔄 Rebalanced exposure away from some mature winners

• 🚀 Rotated capital into Celcuity (+45%) and Alkermes (+26%)

Translation: they’re not married to positions. They’re married to data.

🧱 The Baker Bros. “Science & Sizing” Scorecard (Q3 2025)

🏋️♂️ The Big Three Heavyweights

• Incyte (INCY) (~19%)
  💵 The rare biotech that actually prints money. JAKAFI is a cash-flow engine, not a science experiment.

• BeiGene (BGNE) (~22%)
  🌍 The global oncology disruptor. The Bakers own roughly ~11% of the entire company. That’s not a position—that’s a partnership.

• Madrigal (MDGL) (~7–8%)
  👑 The crown jewel of 2025. Rezdiffra turned a clinical thesis into a commercial story.

Around these sit a deep bench: Acadia Pharmaceuticals, Revolution Medicines, Celcuity, Rhythm, Kymera, Summit, Alkermes, Arrowhead, and others—each a targeted bet on a specific biological pathway, not a vague theme.

🔄 Strategic Rotations: “Feed the Winners, Fund the Future”

• 🫀 The MASH Surge
  They didn’t just hold Madrigal—they increased exposure as risk went down and revenue went up. Classic Baker move.

• 🎯 The Precision Pivot
  A massive +45% increase in Celcuity signals a hunt for the next generation of targeted oncology.

• ✂️ The Trimming Discipline
  Insmed (-13%) and argenx were cut back—not because the science failed, but because capital has to flow where marginal returns look better.

This is portfolio management as capital choreography 💃, not emotional attachment.

🥡 Food for Thought: Lessons from the “Kingmakers”

1️⃣ High Concentration Is How You Get Real Alpha

The Bakers don’t own 1,000 stocks. They own convictions.

📌 Retail lesson:
Stop owning 100 names you barely understand. If you’ve truly done the work on 3–5 companies, sizing up is what separates “interesting hobby” from “actual strategy.”

2️⃣ Batting Average vs. Slugging Percentage ⚾

Historically, the Bakers are wrong more often than right (batting average <50%).
But their win/loss ratio is ~6.7x.

They cut losers fast (small losses) and let winners run (very big gains).

📌 Retail lesson:
You don’t need to be right all the time. You need your winners to matter more than your losers.

3️⃣ The PhD-Level Due Diligence 🧑🔬

Legend has it they show up to meetings with 10 experts and ask questions like:
“What color were the eyes of the patient in that trial?”

📌 Retail lesson:
You won’t out-science the Baker Bros. But you can out-wait the market. Their average holding period is 3+ years. In biotech, money isn’t made in rumors—it’s made in clinical validation and commercial rollout.

4️⃣ Watch the Insider Buys 👀

The Bakers often sit on boards. When they buy more in the open market (as with Madrigal in August 2025), that’s not a “trade.” That’s a declaration.

📌 Retail lesson:
Director purchases aren’t noise. If the smartest people in the room are buying more at $360, they probably don’t think $360 is the destination.

🧾 The FUNanc1al Verdict

The Baker Brothers are the closest thing we have to Biotech Jedi 🧙♂️.
They ignore macro noise, shrug at geopolitical headlines, and focus relentlessly on molecular data. In 2025, they proved—again—that if you own the best science, the market eventually finds you.

For investors, the message is simple (and hard):
Find your “Madrigal.” Do the homework. Then sit on your hands until the world catches up.

⚡ Quick Take / TL;DR

• 🏆 Baker Bros posted a stunning ~67.8% trailing 12-month return in 2025

• 🧬 Portfolio is ultra-concentrated, science-driven, and long-term

• 👑 Madrigal (MDGL) was the breakout star thanks to Rezdiffra

• 🔄 They rotate capital based on data, not emotions

• 📈 You don’t need to be right often—just right big

❓ FAQ

Q: Is Baker Bros too concentrated?
A: That’s the point. Concentration is how they turn insight into impact.

Q: Do they trade often?
A: No. They invest on multi-year clinical and commercial timelines.

Q: Can retail investors copy this?
A: You can’t copy the access—but you can copy the discipline: fewer positions, deeper work, longer horizons. Their portfolio can also be a great idea generator. If Acadia or Alkermes pass the Baker Bros’ sniff test, they probably deserve at least a spot on your research list. 

Q: Is biotech too risky for most people?
A: Only if you treat it like a casino. The Bakers treat it like applied biology.

📌 Important Note on “Returns” and 13F Filings

When FUNanc1al references hedge fund “returns,” we are typically describing the performance of the fund’s public equity holdings as reported in SEC 13F filings and reconstructed by portfolio trackers. This shows how the visible stock positions performed based on market prices—not the fund’s actual, private Net Asset Value (NAV) return to investors.

Hedge funds often hold private investments, cash, hedges, and non-disclosed positions, and they also charge management and performance fees. As a result, a fund’s true investor return can differ—sometimes materially—from the 13F-based “shadow portfolio” performance. In short: 13F returns show how the stocks did; NAV returns show how the fund did—and those are not the same thing.

👤 About the Author

Frédéric Marsanne is the founder of FUNanc1al — part market analyst, part storyteller, part accidental comedian. A longtime investor, entrepreneur, and venture-builder across tech, biotech, and fintech, he blends sharp insights with humor to help readers laugh, learn, live better lives, and invest a little wiser. When not decoding insider buys or poking fun at earnings calls, he’s building Cl1Q, writing fiction, painting, or discovering new passions to FUNalize.

🧾⚠️📢 Fun(anc1al) but Serious Disclaimer: 🧾⚠️📢

This article is for informational and educational purposes only and does not constitute investment advice. Investing involves risk, including the possible loss of principal. Past performance is not predictive. Always do your own research or consult a qualified financial advisor before making investment decisions. Resist FOMO and never invest money you can’t afford to lose. 

We are not hedge fund managers. We do not wear parachutes to rooftop parties. Markets evolve. Machines adapt. Investors should too.

We laugh, we analyze, we meme. 
We’re FUNancial advisors — not financial advisors. 😄📉📈

Invest at your own risk. Love at any pace. Laugh at every turn. 
Be Happy. 😄😄😄

🧭 Looking for a Different Angle?

• 🕵️ Insider Purchases Center
• 📣 Follow the Pundits Hub
• 📈 Young Guns & Turnaround Stocks — Track More Growth (and Growing-Pain) Plays
• 😆 Stock Market Humor & Serious-ish Plays
• 🌍 See the world differently and check out more international market picks and fun takes. Explore International Investment Opportunities and value plays 💸 Cheap Stocks with (Maybe) Big Upside

😂 Laugh, Learn, Invest: funanc1al.com | Funanc1al: Where Even Finance Meets Funny